therapy with-m tor-inhibitors-in-polyomavirus-allograft-nephropathy-(pvan)-a-five-year-follow-up-archives-of-organ-transplantation-peertechz-journals
•Download as PPTX, PDF•
0 likes•52 views
Polyomavirus nephropathy (PVAN) has a negative impact on renal allograft survival. Therapy options include reduction of immunosuppression and antiviral drugs. .
Report
Share
Report
Share
Recommended
Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma ...
This clinical trial compared the combination of nivolumab plus ipilimumab to sunitinib as first-line treatment for advanced renal cell carcinoma. The trial found that nivolumab plus ipilimumab resulted in significantly higher overall survival and objective response rates compared to sunitinib among patients with intermediate- and poor-risk disease. The median overall survival was not reached for nivolumab plus ipilimumab and was 25 months for sunitinib. Treatment-related adverse events occurred more frequently with nivolumab plus ipilimumab but most were grade 1-2. The combination of nivolumab plus ipilimumab represents a new standard of care for advanced renal
Cervical cancer prevention current scenario
Cervical cancer prevention requires a multi-pronged approach including screening, vaccination, and treatment. Screening begins at age 30 through pap smears or HPV testing every 5-10 years and helps detect pre-cancerous lesions early. HPV vaccination targets girls aged 9-13 and has shown nearly 100% efficacy against HPV types 16 and 18, which cause 70% of cervical cancers. Treatment of pre-cancerous lesions can prevent progression to invasive cancer. A comprehensive cervical cancer prevention program should include building healthcare infrastructure, increasing screening coverage, assessing impact, and conducting targeted education campaigns.
2022 02-20-tassid seminar-5 ASA-mesalazine old drug new tricks-dr tsung-chun ...
5-ASA, mesalazine, old drug with new tricks, presented in joint symposium organized by TASSID and TSIBD.
04_Joaquim_Bellmunt.ppsx
This document summarizes an academic presentation on recent therapeutic updates for metastatic urothelial cancer in 2018. It discusses standard of care for second-line treatment and recent results from Phase II and III trials of PD-1/PD-L1 inhibitors. Checkpoint inhibitors like atezolizumab, nivolumab, pembrolizumab, durvalumab and avelumab have received FDA approval for platinum-pretreated or cisplatin-ineligible metastatic urothelial cancer based on trials showing overall response rates of 15-29% and median overall survival of 7.7-15.9 months. Ongoing trials are exploring the potential for predictive biomarkers like PD-L1 expression and
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
Clinical Impact of New Data From CROI 2017
Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.25 MB
Date posted: 3/3/2017
Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivit...
This study examined the effects of consistent condom use following local surgical treatment for cervical intraepithelial neoplasia (CIN). Over 200 women who underwent local excisional treatment for CIN were advised to consistently use condoms for 6 months post-operatively. Biomarkers for HPV (DNA, mRNA E6/E7, p16) were assessed at 6 and 24 months. At 6 months, consistent condom users had lower rates of HPV DNA, mRNA, and p16 positivity compared to inconsistent users. At 24 months, the difference in HPV DNA positivity was more pronounced, with only 13% of consistent users positive versus 71% of inconsistent users. Consistent condom use appeared to reduce
Νικόλαος Τσούλος, MedTech Conference 2021
Ομιλία - Παρουσίαση: “Βιοδείκτες: Η Κλινική τους Αξία και η Σχέση τους με τον ΕΟΠΥΥ”
Νικόλαος Τσούλος, MSc, MBA, Βιοχημικός, Διευθύνων Σύμβουλος GeneKor Medical SA
Management of metastatic colorectal cancer
1) The document discusses treatment strategies for metastatic colorectal cancer (mCRC), including the importance of multidisciplinary teams, sequencing of chemotherapy and targeted therapies, and continuing treatment beyond progression.
2) Key points addressed include using oxaliplatin or irinotecan as the chemotherapy backbone, adding targeted therapies like bevacizumab or anti-EGFR antibodies based on molecular markers, and exploring more intensive strategies like FOLFOXIRI for certain patients.
3) Maintaining quality of life across all treatment lines is emphasized as the overarching goal.
Recommended
Nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma ...
This clinical trial compared the combination of nivolumab plus ipilimumab to sunitinib as first-line treatment for advanced renal cell carcinoma. The trial found that nivolumab plus ipilimumab resulted in significantly higher overall survival and objective response rates compared to sunitinib among patients with intermediate- and poor-risk disease. The median overall survival was not reached for nivolumab plus ipilimumab and was 25 months for sunitinib. Treatment-related adverse events occurred more frequently with nivolumab plus ipilimumab but most were grade 1-2. The combination of nivolumab plus ipilimumab represents a new standard of care for advanced renal
Cervical cancer prevention current scenario
Cervical cancer prevention requires a multi-pronged approach including screening, vaccination, and treatment. Screening begins at age 30 through pap smears or HPV testing every 5-10 years and helps detect pre-cancerous lesions early. HPV vaccination targets girls aged 9-13 and has shown nearly 100% efficacy against HPV types 16 and 18, which cause 70% of cervical cancers. Treatment of pre-cancerous lesions can prevent progression to invasive cancer. A comprehensive cervical cancer prevention program should include building healthcare infrastructure, increasing screening coverage, assessing impact, and conducting targeted education campaigns.
2022 02-20-tassid seminar-5 ASA-mesalazine old drug new tricks-dr tsung-chun ...
5-ASA, mesalazine, old drug with new tricks, presented in joint symposium organized by TASSID and TSIBD.
04_Joaquim_Bellmunt.ppsx
This document summarizes an academic presentation on recent therapeutic updates for metastatic urothelial cancer in 2018. It discusses standard of care for second-line treatment and recent results from Phase II and III trials of PD-1/PD-L1 inhibitors. Checkpoint inhibitors like atezolizumab, nivolumab, pembrolizumab, durvalumab and avelumab have received FDA approval for platinum-pretreated or cisplatin-ineligible metastatic urothelial cancer based on trials showing overall response rates of 15-29% and median overall survival of 7.7-15.9 months. Ongoing trials are exploring the potential for predictive biomarkers like PD-L1 expression and
Новые данные с конференции по ВИЧ-инфекции CROI 2017/Clinical Impact of New D...
Clinical Impact of New Data From CROI 2017
Expert faculty members Joel E. Gallant, MD, MPH, and Charles B. Hicks, MD, summarize key studies from this important annual conference.
Format: Microsoft PowerPoint (.ppt)
File size: 1.25 MB
Date posted: 3/3/2017
Effect of Condom Use after CIN Treatment on Cervical HPV Biomarkers Positivit...
This study examined the effects of consistent condom use following local surgical treatment for cervical intraepithelial neoplasia (CIN). Over 200 women who underwent local excisional treatment for CIN were advised to consistently use condoms for 6 months post-operatively. Biomarkers for HPV (DNA, mRNA E6/E7, p16) were assessed at 6 and 24 months. At 6 months, consistent condom users had lower rates of HPV DNA, mRNA, and p16 positivity compared to inconsistent users. At 24 months, the difference in HPV DNA positivity was more pronounced, with only 13% of consistent users positive versus 71% of inconsistent users. Consistent condom use appeared to reduce
Νικόλαος Τσούλος, MedTech Conference 2021
Ομιλία - Παρουσίαση: “Βιοδείκτες: Η Κλινική τους Αξία και η Σχέση τους με τον ΕΟΠΥΥ”
Νικόλαος Τσούλος, MSc, MBA, Βιοχημικός, Διευθύνων Σύμβουλος GeneKor Medical SA
Management of metastatic colorectal cancer
1) The document discusses treatment strategies for metastatic colorectal cancer (mCRC), including the importance of multidisciplinary teams, sequencing of chemotherapy and targeted therapies, and continuing treatment beyond progression.
2) Key points addressed include using oxaliplatin or irinotecan as the chemotherapy backbone, adding targeted therapies like bevacizumab or anti-EGFR antibodies based on molecular markers, and exploring more intensive strategies like FOLFOXIRI for certain patients.
3) Maintaining quality of life across all treatment lines is emphasized as the overarching goal.
Mesothelioma - Multidisciplinary Treatment Update
In this program, Dr. Michele Carbone examines the causes of mesothelioma and potential prevention strategies.
Gene sequencing and tb – a new age approach.pptx
Whole genome sequencing is increasingly being used to diagnose drug-resistant tuberculosis. It can identify resistance across all anti-TB drugs through DNA sequencing of the entire TB genome. This overcomes limitations of other tests and provides personalized treatment by rapidly detecting mixed infections, co-infections, and heteroresistance. While expensive and technically complex, whole genome sequencing improves treatment outcomes and aids in prevention by better understanding transmission.
Contemporary Management of HIV. New Data From AIDS 2018
This document summarizes key findings from the AIDS 2018 conference regarding contemporary management of HIV. It describes studies showing:
1) No linked HIV transmissions occurred in over 77,000 condomless sex acts when the HIV+ partner had an undetectable viral load in the PARTNER2 study.
2) On-demand PrEP was highly effective at preventing HIV in several studies when adherence was high.
3) Early results from the ANRS Prevenir study found no difference in HIV incidence between daily and on-demand PrEP, with high adherence in both groups.
CRC Case Closed Presentation.pdf
This document summarizes a presentation on utilizing biomarkers in the management of metastatic colorectal cancer. It discusses three cases involving patients with metastatic colorectal cancer. For the first case, the necessary molecular testing is determined to be testing for all RAS mutations, BRAFV600E, MMR/MSI, and HER2 amplification. For the second case, the next best treatment for a patient with HER2-positive disease is determined to be Trastuzumab + Lapatinib, Trastuzumab + Pertuzumab, or Trastuzumab Deruxtecan. For the third case, the treatment approach depends on whether an NTRK gene fusion is identified.
Continuum of care of metastatic colorectal cancer
Describes management of metastatic colorectal cancer in subsequent treatment lines beyond the first line treatment.
Next generation sequencing in cancer treatment
Next-generation sequencing (NGS) provides several advantages over first generation sequencing methods. NGS allows large amounts of genomic information to be sequenced in parallel at a lower cost. NGS has various applications in cancer treatment including predicting cancer progression, identifying drug targets and resistance mutations, detecting minimal residual disease, and improving cancer classification. While powerful, NGS also faces limitations such as tissue heterogeneity, complexity of data analysis, and difficulties identifying driver mutations as cancers evolve with treatment.
The CIBMTR score predicts survival of AML patients undergoing allogeneic tran...
This study retrospectively analyzed 523 acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation with active disease from 20 Italian centers to validate the CIBMTR pre-transplantation risk score. The CIBMTR score uses 5 pre-transplant variables to stratify patients into groups with 3-year overall survival rates ranging from 42% to 6%. The study found the CIBMTR score predicted survival in this cohort, with hazard ratios confirming worse survival for shorter first complete remission duration, non-sibling donor, higher blast percentage, and lower Karnofsky score. Multivariate analysis validated the CIBMTR score as prognostic for this larger patient population including both myeloabl
Colon cancer sidedness 2018
It describes the relevant data upon choice of therapy in relation to primary tumor location (Right and Left Sided Colon Cancer)
Impact of Tumor Location in CRC on Treatment Decision
Describes the most recent evidence that tumor location in metastatic colorectal cancer would affect the treatment decision.
Impact of 1ry tumor location on treatment guidelines of mCRC
The document summarizes key findings from a presentation on the impact of primary tumor location on treatment guidelines for metastatic colorectal cancer (mCRC). Some main points include:
- Left-sided mCRC is associated with better outcomes than right-sided mCRC based on several studies and meta-analyses.
- Differences in embryology, blood supply, nodal drainage, microbiome, pre-cancerous lesions, molecular subtypes and histopathology between right and left colon tumors may explain the outcome disparity.
- Adding anti-EGFR monoclonal antibodies to chemotherapy appears to provide a greater benefit for left-sided mCRC compared to right-sided disease based on several studies.
- The role
mycv2016
This document provides an extensive biography for Mayra G. Oberto-Medina, including her education, certifications, professional experience, research, publications, affiliations, conferences, college activities, languages, and hobbies. She has over 20 years of experience as a rheumatologist and has participated in numerous clinical trials and research studies.
Integration of NGS in Current & FutureTreatment Algorithm of Colorectal Cancer
Describes the emerging role of sequencing technology in prognostic stratification and therapeutic implications in colorectal cancer
Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...
1) An analysis was conducted of malignancy data from clinical trials of tofacitinib, an oral Janus kinase inhibitor for rheumatoid arthritis (RA). Over 5,600 patients were treated with tofacitinib across phase 2, 3, and long-term extension studies.
2) 107 patients treated with tofacitinib developed malignancies excluding non-melanoma skin cancer (NMSC), with rates similar to those expected in RA patients and the general population. The most common malignancies were lung cancer, breast cancer, and lymphoma.
3) The incidence of malignancies was stable over time with tofacitinib exposure and was not higher than placebo or the active control ad
Secuencia en cáncer de colon metastásico
This document summarizes a presentation on the best treatment sequences for incurable colon cancer. It discusses several studies comparing chemotherapy plus bevacizumab or cetuximab as first-line treatment. The studies show better outcomes with cetuximab for left-sided tumors but no difference or possible benefit of bevacizumab for right-sided tumors. It also discusses using molecular subtyping and BRAF mutation status to guide treatment selections and the potential for anti-PD1 therapy in mismatch repair deficient tumors.
British J Pharmacology - 2021 - Healy - The importance of Ras in drug resista...
This document discusses drug resistance in cancer that is mediated by oncogenic Ras mutations. It covers several key points:
1) Ras mutations can cause intrinsic and acquired resistance to chemotherapy and targeted therapies by constitutively activating proliferative and survival pathways. This resistance occurs across many cancer types.
2) Ras mutations contribute to the survival of cancer stem cells through pathways like Wnt/β-catenin and MAPK that promote stem cell self-renewal. Cancer stem cells are intrinsically resistant to chemotherapy.
3) Examples of drug resistance caused by downstream Ras mutations include resistance to EGFR inhibitors in cancers where Ras operates downstream of EGFR. Combination therapies may help prevent resistance arising from minor tumor subclones
A SEEMINGLY BENIGN DRUG IN THE SPOTLIGHT: AN EDUCATIONAL INTERVENTION TO REDU...
INTRODUCTION
Overutilization of Proton pump inhibitors (PPI) in hospitalized patients is a well-recognized problem. In our previous study at St. Luke’s Hospital, we found that the lack of published guidelines for PPI use in non-critically ill patients results in overutilization of PPI in hospitalized patients. We conducted an educational intervention program to address this problem.
DISCUSSION
Overutilization of PPI in non-critically ill hospitalized patients is a known problem in medical practice. Use of PPI has been implicated in number of adverse consequences including but not limited to Clostridium difficile infection, pneumonia, and osteoporosis. In recent studies, PPI was found to be associated with increased in-hospital mortality, increased risk of cardiovascular events, dementia and chronic renal failure (CRF). We studied the magnitude of the problem in our hospital and employed an educational intervention program, which resulted in a significant reduction of inappropriate use of PPI in the hospital.
There were several limitations to our study. This was a retrospective study where we noted a lack of proper documentation for outpatient use of PPI. We also were unable to precisely determine for how long the patients were taking PPI as outpatients. Our intervention included only medical residents (a total of 41), so we excluded data from NPs, hospitalists or PCPs after intervention. As a result, we are unable to determine the effect of the educational intervention on their practice.
CONCLUSION
PPIs have long been considered as relatively harmless drugs. In recent years, it has been implicated in several adverse effects that increases patient morbidity and mortality along with increased healthcare expenditure. Our data shows that proper education and ongoing surveillance, especially during admission and discharge can significantly reduce overutilization of PPI.
Antiangiogenic Therapy in colorectal cancer
1) Anti-angiogenic therapy targets tumor angiogenesis and has become an established treatment for metastatic colorectal cancer (mCRC).
2) Bevacizumab, a monoclonal antibody targeting VEGF, has shown efficacy in multiple phase III trials in combination with chemotherapy as first-line and maintenance therapy for mCRC.
3) Additional anti-angiogenic agents approved for mCRC include aflibercept, ramucirumab, and regorafinib, which have demonstrated benefits in later lines of therapy.
Современное лечение ВИЧ.Объединенные данные с конференции IAS 2019 / Contemp...
Review key HIV data from IAS 2019 on the updated NTD risk in women receiving ART at conception, PrEP, first-line and switch options, and early-phase investigational strategies.
Prophylaxis and HIV Prevention by Dr. Ken Mayer
Pre and Post Exposure Prophylaxis and HIV Prevention presented by Dr. Ken Mayer, Research Director of the Fenway Health Center at the Fenway Health Center community education conference: An End To AIDS - How A State Bill Can Change Everything hosted by SearchForACure.org, the Fenway Health Center, and the MA Dept. of Public Health
Targeted Therapy for Melanoma - Dr. Michael Davies
Dr. Michael Davies presents the latest information on targeted melanoma therapies at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
HUMAN EYE By-R.M Class 10 phy best digital notes.pdf
Class 10 human eye notes physics
Handwritten best quality
BIRDS DIVERSITY OF SOOTEA BISWANATH ASSAM.ppt.pptx
Ahota Beel, nestled in Sootea Biswanath Assam , is celebrated for its extraordinary diversity of bird species. This wetland sanctuary supports a myriad of avian residents and migrants alike. Visitors can admire the elegant flights of migratory species such as the Northern Pintail and Eurasian Wigeon, alongside resident birds including the Asian Openbill and Pheasant-tailed Jacana. With its tranquil scenery and varied habitats, Ahota Beel offers a perfect haven for birdwatchers to appreciate and study the vibrant birdlife that thrives in this natural refuge.
More Related Content
Similar to therapy with-m tor-inhibitors-in-polyomavirus-allograft-nephropathy-(pvan)-a-five-year-follow-up-archives-of-organ-transplantation-peertechz-journals
Mesothelioma - Multidisciplinary Treatment Update
In this program, Dr. Michele Carbone examines the causes of mesothelioma and potential prevention strategies.
Gene sequencing and tb – a new age approach.pptx
Whole genome sequencing is increasingly being used to diagnose drug-resistant tuberculosis. It can identify resistance across all anti-TB drugs through DNA sequencing of the entire TB genome. This overcomes limitations of other tests and provides personalized treatment by rapidly detecting mixed infections, co-infections, and heteroresistance. While expensive and technically complex, whole genome sequencing improves treatment outcomes and aids in prevention by better understanding transmission.
Contemporary Management of HIV. New Data From AIDS 2018
This document summarizes key findings from the AIDS 2018 conference regarding contemporary management of HIV. It describes studies showing:
1) No linked HIV transmissions occurred in over 77,000 condomless sex acts when the HIV+ partner had an undetectable viral load in the PARTNER2 study.
2) On-demand PrEP was highly effective at preventing HIV in several studies when adherence was high.
3) Early results from the ANRS Prevenir study found no difference in HIV incidence between daily and on-demand PrEP, with high adherence in both groups.
CRC Case Closed Presentation.pdf
This document summarizes a presentation on utilizing biomarkers in the management of metastatic colorectal cancer. It discusses three cases involving patients with metastatic colorectal cancer. For the first case, the necessary molecular testing is determined to be testing for all RAS mutations, BRAFV600E, MMR/MSI, and HER2 amplification. For the second case, the next best treatment for a patient with HER2-positive disease is determined to be Trastuzumab + Lapatinib, Trastuzumab + Pertuzumab, or Trastuzumab Deruxtecan. For the third case, the treatment approach depends on whether an NTRK gene fusion is identified.
Continuum of care of metastatic colorectal cancer
Describes management of metastatic colorectal cancer in subsequent treatment lines beyond the first line treatment.
Next generation sequencing in cancer treatment
Next-generation sequencing (NGS) provides several advantages over first generation sequencing methods. NGS allows large amounts of genomic information to be sequenced in parallel at a lower cost. NGS has various applications in cancer treatment including predicting cancer progression, identifying drug targets and resistance mutations, detecting minimal residual disease, and improving cancer classification. While powerful, NGS also faces limitations such as tissue heterogeneity, complexity of data analysis, and difficulties identifying driver mutations as cancers evolve with treatment.
The CIBMTR score predicts survival of AML patients undergoing allogeneic tran...
This study retrospectively analyzed 523 acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation with active disease from 20 Italian centers to validate the CIBMTR pre-transplantation risk score. The CIBMTR score uses 5 pre-transplant variables to stratify patients into groups with 3-year overall survival rates ranging from 42% to 6%. The study found the CIBMTR score predicted survival in this cohort, with hazard ratios confirming worse survival for shorter first complete remission duration, non-sibling donor, higher blast percentage, and lower Karnofsky score. Multivariate analysis validated the CIBMTR score as prognostic for this larger patient population including both myeloabl
Colon cancer sidedness 2018
It describes the relevant data upon choice of therapy in relation to primary tumor location (Right and Left Sided Colon Cancer)
Impact of Tumor Location in CRC on Treatment Decision
Describes the most recent evidence that tumor location in metastatic colorectal cancer would affect the treatment decision.
Impact of 1ry tumor location on treatment guidelines of mCRC
The document summarizes key findings from a presentation on the impact of primary tumor location on treatment guidelines for metastatic colorectal cancer (mCRC). Some main points include:
- Left-sided mCRC is associated with better outcomes than right-sided mCRC based on several studies and meta-analyses.
- Differences in embryology, blood supply, nodal drainage, microbiome, pre-cancerous lesions, molecular subtypes and histopathology between right and left colon tumors may explain the outcome disparity.
- Adding anti-EGFR monoclonal antibodies to chemotherapy appears to provide a greater benefit for left-sided mCRC compared to right-sided disease based on several studies.
- The role
mycv2016
This document provides an extensive biography for Mayra G. Oberto-Medina, including her education, certifications, professional experience, research, publications, affiliations, conferences, college activities, languages, and hobbies. She has over 20 years of experience as a rheumatologist and has participated in numerous clinical trials and research studies.
Integration of NGS in Current & FutureTreatment Algorithm of Colorectal Cancer
Describes the emerging role of sequencing technology in prognostic stratification and therapeutic implications in colorectal cancer
Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...
1) An analysis was conducted of malignancy data from clinical trials of tofacitinib, an oral Janus kinase inhibitor for rheumatoid arthritis (RA). Over 5,600 patients were treated with tofacitinib across phase 2, 3, and long-term extension studies.
2) 107 patients treated with tofacitinib developed malignancies excluding non-melanoma skin cancer (NMSC), with rates similar to those expected in RA patients and the general population. The most common malignancies were lung cancer, breast cancer, and lymphoma.
3) The incidence of malignancies was stable over time with tofacitinib exposure and was not higher than placebo or the active control ad
Secuencia en cáncer de colon metastásico
This document summarizes a presentation on the best treatment sequences for incurable colon cancer. It discusses several studies comparing chemotherapy plus bevacizumab or cetuximab as first-line treatment. The studies show better outcomes with cetuximab for left-sided tumors but no difference or possible benefit of bevacizumab for right-sided tumors. It also discusses using molecular subtyping and BRAF mutation status to guide treatment selections and the potential for anti-PD1 therapy in mismatch repair deficient tumors.
British J Pharmacology - 2021 - Healy - The importance of Ras in drug resista...
This document discusses drug resistance in cancer that is mediated by oncogenic Ras mutations. It covers several key points:
1) Ras mutations can cause intrinsic and acquired resistance to chemotherapy and targeted therapies by constitutively activating proliferative and survival pathways. This resistance occurs across many cancer types.
2) Ras mutations contribute to the survival of cancer stem cells through pathways like Wnt/β-catenin and MAPK that promote stem cell self-renewal. Cancer stem cells are intrinsically resistant to chemotherapy.
3) Examples of drug resistance caused by downstream Ras mutations include resistance to EGFR inhibitors in cancers where Ras operates downstream of EGFR. Combination therapies may help prevent resistance arising from minor tumor subclones
A SEEMINGLY BENIGN DRUG IN THE SPOTLIGHT: AN EDUCATIONAL INTERVENTION TO REDU...
INTRODUCTION
Overutilization of Proton pump inhibitors (PPI) in hospitalized patients is a well-recognized problem. In our previous study at St. Luke’s Hospital, we found that the lack of published guidelines for PPI use in non-critically ill patients results in overutilization of PPI in hospitalized patients. We conducted an educational intervention program to address this problem.
DISCUSSION
Overutilization of PPI in non-critically ill hospitalized patients is a known problem in medical practice. Use of PPI has been implicated in number of adverse consequences including but not limited to Clostridium difficile infection, pneumonia, and osteoporosis. In recent studies, PPI was found to be associated with increased in-hospital mortality, increased risk of cardiovascular events, dementia and chronic renal failure (CRF). We studied the magnitude of the problem in our hospital and employed an educational intervention program, which resulted in a significant reduction of inappropriate use of PPI in the hospital.
There were several limitations to our study. This was a retrospective study where we noted a lack of proper documentation for outpatient use of PPI. We also were unable to precisely determine for how long the patients were taking PPI as outpatients. Our intervention included only medical residents (a total of 41), so we excluded data from NPs, hospitalists or PCPs after intervention. As a result, we are unable to determine the effect of the educational intervention on their practice.
CONCLUSION
PPIs have long been considered as relatively harmless drugs. In recent years, it has been implicated in several adverse effects that increases patient morbidity and mortality along with increased healthcare expenditure. Our data shows that proper education and ongoing surveillance, especially during admission and discharge can significantly reduce overutilization of PPI.
Antiangiogenic Therapy in colorectal cancer
1) Anti-angiogenic therapy targets tumor angiogenesis and has become an established treatment for metastatic colorectal cancer (mCRC).
2) Bevacizumab, a monoclonal antibody targeting VEGF, has shown efficacy in multiple phase III trials in combination with chemotherapy as first-line and maintenance therapy for mCRC.
3) Additional anti-angiogenic agents approved for mCRC include aflibercept, ramucirumab, and regorafinib, which have demonstrated benefits in later lines of therapy.
Современное лечение ВИЧ.Объединенные данные с конференции IAS 2019 / Contemp...
Review key HIV data from IAS 2019 on the updated NTD risk in women receiving ART at conception, PrEP, first-line and switch options, and early-phase investigational strategies.
Prophylaxis and HIV Prevention by Dr. Ken Mayer
Pre and Post Exposure Prophylaxis and HIV Prevention presented by Dr. Ken Mayer, Research Director of the Fenway Health Center at the Fenway Health Center community education conference: An End To AIDS - How A State Bill Can Change Everything hosted by SearchForACure.org, the Fenway Health Center, and the MA Dept. of Public Health
Targeted Therapy for Melanoma - Dr. Michael Davies
Dr. Michael Davies presents the latest information on targeted melanoma therapies at the MRF's Patient Symposium at MD Anderson Cancer Center on January 31, 2015.
Similar to therapy with-m tor-inhibitors-in-polyomavirus-allograft-nephropathy-(pvan)-a-five-year-follow-up-archives-of-organ-transplantation-peertechz-journals (20)
Contemporary Management of HIV. New Data From AIDS 2018
Contemporary Management of HIV. New Data From AIDS 2018
The CIBMTR score predicts survival of AML patients undergoing allogeneic tran...
The CIBMTR score predicts survival of AML patients undergoing allogeneic tran...
Impact of Tumor Location in CRC on Treatment Decision
Impact of Tumor Location in CRC on Treatment Decision
Impact of 1ry tumor location on treatment guidelines of mCRC
Impact of 1ry tumor location on treatment guidelines of mCRC
Integration of NGS in Current & FutureTreatment Algorithm of Colorectal Cancer
Integration of NGS in Current & FutureTreatment Algorithm of Colorectal Cancer
Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...
Tofacitinib, an oral janus kinase inhibitor, analysis of malignancies across ...
British J Pharmacology - 2021 - Healy - The importance of Ras in drug resista...
British J Pharmacology - 2021 - Healy - The importance of Ras in drug resista...
A SEEMINGLY BENIGN DRUG IN THE SPOTLIGHT: AN EDUCATIONAL INTERVENTION TO REDU...
A SEEMINGLY BENIGN DRUG IN THE SPOTLIGHT: AN EDUCATIONAL INTERVENTION TO REDU...
Современное лечение ВИЧ.Объединенные данные с конференции IAS 2019 / Contemp...
Современное лечение ВИЧ.Объединенные данные с конференции IAS 2019 / Contemp...
Targeted Therapy for Melanoma - Dr. Michael Davies
Targeted Therapy for Melanoma - Dr. Michael Davies
Recently uploaded
HUMAN EYE By-R.M Class 10 phy best digital notes.pdf
Class 10 human eye notes physics
Handwritten best quality
BIRDS DIVERSITY OF SOOTEA BISWANATH ASSAM.ppt.pptx
Ahota Beel, nestled in Sootea Biswanath Assam , is celebrated for its extraordinary diversity of bird species. This wetland sanctuary supports a myriad of avian residents and migrants alike. Visitors can admire the elegant flights of migratory species such as the Northern Pintail and Eurasian Wigeon, alongside resident birds including the Asian Openbill and Pheasant-tailed Jacana. With its tranquil scenery and varied habitats, Ahota Beel offers a perfect haven for birdwatchers to appreciate and study the vibrant birdlife that thrives in this natural refuge.
Holsinger, Bruce W. - Music, body and desire in medieval culture [2001].pdf
Music and Medieval History
Farming systems analysis: what have we learnt?.pptx
Presentation given at the official farewell of Prof Ken Gillet at Wageningen on 13 June 2024
Post translation modification by Suyash Garg
overview of PTM helps to the students who wants to clear their basics about it.
Discovery of An Apparent Red, High-Velocity Type Ia Supernova at 𝐳 = 2.9 wi...
We present the JWST discovery of SN 2023adsy, a transient object located in a host galaxy JADES-GS
+
53.13485
−
27.82088
with a host spectroscopic redshift of
2.903
±
0.007
. The transient was identified in deep James Webb Space Telescope (JWST)/NIRCam imaging from the JWST Advanced Deep Extragalactic Survey (JADES) program. Photometric and spectroscopic followup with NIRCam and NIRSpec, respectively, confirm the redshift and yield UV-NIR light-curve, NIR color, and spectroscopic information all consistent with a Type Ia classification. Despite its classification as a likely SN Ia, SN 2023adsy is both fairly red (
�
(
�
−
�
)
∼
0.9
) despite a host galaxy with low-extinction and has a high Ca II velocity (
19
,
000
±
2
,
000
km/s) compared to the general population of SNe Ia. While these characteristics are consistent with some Ca-rich SNe Ia, particularly SN 2016hnk, SN 2023adsy is intrinsically brighter than the low-
�
Ca-rich population. Although such an object is too red for any low-
�
cosmological sample, we apply a fiducial standardization approach to SN 2023adsy and find that the SN 2023adsy luminosity distance measurement is in excellent agreement (
≲
1
�
) with
Λ
CDM. Therefore unlike low-
�
Ca-rich SNe Ia, SN 2023adsy is standardizable and gives no indication that SN Ia standardized luminosities change significantly with redshift. A larger sample of distant SNe Ia is required to determine if SN Ia population characteristics at high-
�
truly diverge from their low-
�
counterparts, and to confirm that standardized luminosities nevertheless remain constant with redshift.
Pests of Storage_Identification_Dr.UPR.pdf
InIndia-post-harvestlosses-unscientificstorage,insects,rodents,micro-organismsetc.,accountforabout10percentoftotalfoodgrains
Graininfestation
Directdamage
Indirectly
•theexuviae,skin,deadinsects
•theirexcretawhichmakefoodunfitforhumanconsumption
About600speciesofinsectshavebeenassociatedwithstoredgrainproducts
100speciesofinsectpestsofstoredproductscauseeconomiclosses
SDSS1335+0728: The awakening of a ∼ 106M⊙ black hole⋆
Context. The early-type galaxy SDSS J133519.91+072807.4 (hereafter SDSS1335+0728), which had exhibited no prior optical variations during the preceding two decades, began showing significant nuclear variability in the Zwicky Transient Facility (ZTF) alert stream from December 2019 (as ZTF19acnskyy). This variability behaviour, coupled with the host-galaxy properties, suggests that SDSS1335+0728 hosts a ∼ 106M⊙ black hole (BH) that is currently in the process of ‘turning on’. Aims. We present a multi-wavelength photometric analysis and spectroscopic follow-up performed with the aim of better understanding the origin of the nuclear variations detected in SDSS1335+0728. Methods. We used archival photometry (from WISE, 2MASS, SDSS, GALEX, eROSITA) and spectroscopic data (from SDSS and LAMOST) to study the state of SDSS1335+0728 prior to December 2019, and new observations from Swift, SOAR/Goodman, VLT/X-shooter, and Keck/LRIS taken after its turn-on to characterise its current state. We analysed the variability of SDSS1335+0728 in the X-ray/UV/optical/mid-infrared range, modelled its spectral energy distribution prior to and after December 2019, and studied the evolution of its UV/optical spectra. Results. From our multi-wavelength photometric analysis, we find that: (a) since 2021, the UV flux (from Swift/UVOT observations) is four times brighter than the flux reported by GALEX in 2004; (b) since June 2022, the mid-infrared flux has risen more than two times, and the W1−W2 WISE colour has become redder; and (c) since February 2024, the source has begun showing X-ray emission. From our spectroscopic follow-up, we see that (i) the narrow emission line ratios are now consistent with a more energetic ionising continuum; (ii) broad emission lines are not detected; and (iii) the [OIII] line increased its flux ∼ 3.6 years after the first ZTF alert, which implies a relatively compact narrow-line-emitting region. Conclusions. We conclude that the variations observed in SDSS1335+0728 could be either explained by a ∼ 106M⊙ AGN that is just turning on or by an exotic tidal disruption event (TDE). If the former is true, SDSS1335+0728 is one of the strongest cases of an AGNobserved in the process of activating. If the latter were found to be the case, it would correspond to the longest and faintest TDE ever observed (or another class of still unknown nuclear transient). Future observations of SDSS1335+0728 are crucial to further understand its behaviour. Key words. galaxies: active– accretion, accretion discs– galaxies: individual: SDSS J133519.91+072807.4
Quality assurance B.pharm 6th semester BP606T UNIT 5
Warehousing
Good warehousing practices
Material management
The cost of acquiring information by natural selection
This is a short talk that I gave at the Banff International Research Station workshop on Modeling and Theory in Population Biology. The idea is to try to understand how the burden of natural selection relates to the amount of information that selection puts into the genome.
It's based on the first part of this research paper:
The cost of information acquisition by natural selection
Ryan Seamus McGee, Olivia Kosterlitz, Artem Kaznatcheev, Benjamin Kerr, Carl T. Bergstrom
bioRxiv 2022.07.02.498577; doi: https://doi.org/10.1101/2022.07.02.498577
Injection: Risks and challenges - Injection of CO2 into geological rock forma...
Presentation by Dr. Florian Krob, Workshop "Risks of CO2 storage - How can they be addressed and reduced?", 22.4.2024
Sexuality - Issues, Attitude and Behaviour - Applied Social Psychology - Psyc...
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Context. The observation of several L-band emission sources in the S cluster has led to a rich discussion of their nature. However, a definitive answer to the classification of the dusty objects requires an explanation for the detection of compact Doppler-shifted Brγ emission. The ionized hydrogen in combination with the observation of mid-infrared L-band continuum emission suggests that most of these sources are embedded in a dusty envelope. These embedded sources are part of the S-cluster, and their relationship to the S-stars is still under debate. To date, the question of the origin of these two populations has been vague, although all explanations favor migration processes for the individual cluster members. Aims. This work revisits the S-cluster and its dusty members orbiting the supermassive black hole SgrA* on bound Keplerian orbits from a kinematic perspective. The aim is to explore the Keplerian parameters for patterns that might imply a nonrandom distribution of the sample. Additionally, various analytical aspects are considered to address the nature of the dusty sources. Methods. Based on the photometric analysis, we estimated the individual H−K and K−L colors for the source sample and compared the results to known cluster members. The classification revealed a noticeable contrast between the S-stars and the dusty sources. To fit the flux-density distribution, we utilized the radiative transfer code HYPERION and implemented a young stellar object Class I model. We obtained the position angle from the Keplerian fit results; additionally, we analyzed the distribution of the inclinations and the longitudes of the ascending node. Results. The colors of the dusty sources suggest a stellar nature consistent with the spectral energy distribution in the near and midinfrared domains. Furthermore, the evaporation timescales of dusty and gaseous clumps in the vicinity of SgrA* are much shorter ( 2yr) than the epochs covered by the observations (≈15yr). In addition to the strong evidence for the stellar classification of the D-sources, we also find a clear disk-like pattern following the arrangements of S-stars proposed in the literature. Furthermore, we find a global intrinsic inclination for all dusty sources of 60 ± 20◦, implying a common formation process. Conclusions. The pattern of the dusty sources manifested in the distribution of the position angles, inclinations, and longitudes of the ascending node strongly suggests two different scenarios: the main-sequence stars and the dusty stellar S-cluster sources share a common formation history or migrated with a similar formation channel in the vicinity of SgrA*. Alternatively, the gravitational influence of SgrA* in combination with a massive perturber, such as a putative intermediate mass black hole in the IRS 13 cluster, forces the dusty objects and S-stars to follow a particular orbital arrangement. Key words. stars: black holes– stars: formation– Galaxy: center– galaxies: star formation
fermented food science of sauerkraut.pptx
This ppt contains the production of a fermented food name - sauerkraut
Recently uploaded (20)
HUMAN EYE By-R.M Class 10 phy best digital notes.pdf
HUMAN EYE By-R.M Class 10 phy best digital notes.pdf
BIRDS DIVERSITY OF SOOTEA BISWANATH ASSAM.ppt.pptx
BIRDS DIVERSITY OF SOOTEA BISWANATH ASSAM.ppt.pptx
Holsinger, Bruce W. - Music, body and desire in medieval culture [2001].pdf
Holsinger, Bruce W. - Music, body and desire in medieval culture [2001].pdf
Farming systems analysis: what have we learnt?.pptx
Farming systems analysis: what have we learnt?.pptx
Discovery of An Apparent Red, High-Velocity Type Ia Supernova at 𝐳 = 2.9 wi...
Discovery of An Apparent Red, High-Velocity Type Ia Supernova at 𝐳 = 2.9 wi...
SDSS1335+0728: The awakening of a ∼ 106M⊙ black hole⋆
SDSS1335+0728: The awakening of a ∼ 106M⊙ black hole⋆
Quality assurance B.pharm 6th semester BP606T UNIT 5
Quality assurance B.pharm 6th semester BP606T UNIT 5
The cost of acquiring information by natural selection
The cost of acquiring information by natural selection
Injection: Risks and challenges - Injection of CO2 into geological rock forma...
Injection: Risks and challenges - Injection of CO2 into geological rock forma...
Microbiology of Central Nervous System INFECTIONS.pdf
Microbiology of Central Nervous System INFECTIONS.pdf
Sexuality - Issues, Attitude and Behaviour - Applied Social Psychology - Psyc...
Sexuality - Issues, Attitude and Behaviour - Applied Social Psychology - Psyc...
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Candidate young stellar objects in the S-cluster: Kinematic analysis of a sub...
Introduction_Ch_01_Biotech Biotechnology course .pptx
Introduction_Ch_01_Biotech Biotechnology course .pptx
therapy with-m tor-inhibitors-in-polyomavirus-allograft-nephropathy-(pvan)-a-five-year-follow-up-archives-of-organ-transplantation-peertechz-journals
- 1. Archives of Organ Transplantation Peertechz Journals
- 2. Case Report Therapy with mTOR Inhibitors in Polyomavirus Allograft Nephropathy (PVAN): A Five Year Follow Up Ana Theresa Guanaes Bonini, André Barros Albuquerque Esteves, Leonardo Figueiredo Camargo, Carla Feitosa do Valle, Gabriel Giollo Rivelli, Marcos Vinícius de Sousa and Marilda Mazzali* *Corresponding author: Marilda Mazzali, Division of Nephrology, Department of Medicine, School of Medical Sciences, University of Campinas- DCM/FCM/UNICAMP, Rua Tessalia Vieira de Camargo, 126, Cidade Universitaria Zeferino Vaz, 13083-970- Campinas- Sao Paulo- Brazil, Tel: 55- 19-35218204; Fax: 55-19-3521- 8208; Dates: Received: 15 December, 2016; Accepted: 18 March, 2017; Published: 22 March, 2017 Citation: Bonini ATG, Esteves ABA, Camargo LF, do Valle CF, Rivelli GG, et al. (2017) Therapy with mTOR Inhibitors in Polyomavirus Allograft Nephropathy (PVAN): A Five Year Follow Up. Arch Organ Transplant 2(1): 001-03.
- 3. Abstract Polyomavirus nephropathy (PVAN) has a negative impact on renal allograft survival. Therapy options include reduction of immunosuppression and antiviral drugs. Aim: Evaluate the effect ofmTORi based immunosuppression on PVAN. Methods: Cross-sectional cohort of 21 renaltransplant recipients with PVAN. Initial immunosuppression based on MPA/tacrolimus was changed to mTOR/steroids at diagnosis, if urine protein/creatinine ratio
- 4. Thank you For more information Read Online Article… https://www.peertechz.com/articles/therapy-with-mtor-inhibitors-in- polyomavirus-allograft-nephropathy-pvan-a-five-year-follow-up.pdf For Full Article PDF